GH$111.98
$112.5
Chart
Performance
Key Stats
AI GH Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralGuardant Health shows a mixed investment profile. Strong fundamental growth potential in precision oncology is partially offset by current unprofitability and high valuation. Technical indicators are mixed, suggesting a watchful approach is warranted.
Thematic
Guardant Health is well-positioned within the growing precision oncology and liquid biopsy market. Advancements in cancer detection and personalized treatment offer significant long-term growth potential.
Fundamental
Guardant Health demonstrates strong revenue growth but is currently unprofitable. Its balance sheet shows significant debt relative to equity, and cash flow remains negative.
Technical
Guardant Health's stock has experienced significant volatility. Current price action suggests a potential near-term uptrend, but is battling against longer-term downward price momentum and mixed technical indicators.
| Factor | Score |
|---|---|
| Precision Oncology Growth | 90 |
| Liquid Biopsy Adoption | 85 |
| Healthcare Innovation | 75 |
| Regulatory Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 15 |
| Growth | 80 |
| Balance Sheet Health | 20 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 45 |
| Volume Confirmation | 65 |
| Support & Resistance | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Revenue Growth and Valuation
The company's revenue has grown from $373.65M in 2021 to $739.02M in 2024, and the Price-to-Sales (P/S) ratio has decreased from 33.2 in 2021 to 5.1 in 2024, suggesting improving valuation alongside growth.
Strong Year-to-Date Performance
The stock has achieved a Year-to-Date (YTD) return of 43.19%, indicating strong recent investor interest and performance.
Bearish Points (8)
Consistent Net Losses
The company has reported net losses for all periods from 2021 to 2024, with TTM net income at -$313.92M and 2024 annual net income at -$436.37M.
High Price-to-Sales Ratio
The trailing Price-to-Sales (P/S) ratio is 9.4, and for 2024 it was 5.1, indicating that the company's market value is significantly higher than its revenue, suggesting a premium valuation.
Calendar
July 2025
31
Next Earnings Date
H: $-0.30
A: $-0.51
L: $-0.71
H: 217.50M
A: 211.28M
L: 202.02M
Profile
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Seasonals
Price Target
59.67 USD
The 39 analysts offering 1 year price forecasts for GH have a max estimate of 70.00 and a min estimate of 47.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in non-invasive cancer diagnostics, especially with Cologuard and Oncotype DX, similar market focus on early detection and recurrence monitoring.
Weight: 92
Direct competitor in liquid biopsy, particularly with its Signatera™ platform for minimal residual disease (MRD) monitoring in oncology.
Weight: 90
Leading provider of DNA sequencing technology, a critical enabling platform for Guardant Health's liquid biopsy tests and genomic analysis.
Weight: 88
Major pharmaceutical and diagnostics company with a strong oncology portfolio; owns Foundation Medicine, a direct competitor in genomic profiling and liquid biopsy.